The news of the trial results will be revealed to shareholders and the talking-head analysts (i.e. Adam #$%$stein) - and I use "analysts" loosely here; they are hardly smart or analytical - in August, possibly after the earnings call that month. They submit the NDA paperwork to the FDA in October, likely. The FDA then has "up to six months to review and approve, or not approve" Afrezza. Approval/non-approval would occur around March or April of 2014 (or much earlier as the FDA has so much earlier paperwork on Afrezza already from the prior try for approval). But, yes, $9.00 in August will be a no brainer, and we will go higher thereafter, my opinion, of course.